Takeda Pahrmaceuticals

Takeda Pharmaceutical Company Limited has signed a definitive agreement with Altos Therapeutics LLC.

Acroding to the agreement, the two companies will further develop ATC-1906, an Altos Therapeutics proprietary compound, to provide treatment to the patients suffering from gastroparesis and its symptoms.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Mesoblast Limited has announced that it will raise funds amounting to $44.65m through the private placement of its shares. The placement will be subscribed to by Kentgrove Capital.

The company plans to invest the funds to meet its additional funding requirements for the next three years.

Aslan Pharmaceuticals has raised gross proceeds of $23m in a venture financing round.

The company plans to use the funds for clinical development of its products in the pipeline for treating highly-prevalent tumour types in Asia.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“The company plans to use the funds for clinical development of its products in the pipeline for treating highly-prevalent tumour types in Asia.”

Nantong jinghua Pharmaceuticals plans to offer a private placement of its share to raise up to $120.4m.

The company plans to use the proceeds to acquire Alpha Pharma.

Pharmaceutical product manufacturer Huons Global has announced a public offering of its 4,959,779 common stock shares.

The company plans to raise funds amounting to $250m from the offering, which is expected to be completed by 10 August 2016.


Image: Takeda Pharmaceutical Company Limited has signed a definitive agreement with Altos Therapeutics LLC. Photo : Courtesy of Lombroso.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact